Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | CFD | P00746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12534165 | 0.83 | LMNA (0.33) | LMNACYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL28935960 | 0.76 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL18780525 | 0.75 | HTR2A (0.33) | LMNATP53HTT | |
| SCHEMBL24989692 | 0.75 | CFD (0.47) | LMNACYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL18310663 | 0.71 | EIF4A3 (0.35) | LMNACYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL20072503 | 0.71 | LMNA (0.39) | LMNATP53HTTPDE2A | |
| SCHEMBL21239903 | 0.71 | LMNA (0.39) | LMNATP53HTTPDE2A | |
| SCHEMBL24039916 | 0.71 | CYP1A2 (0.39) | LMNACYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL21567158 | 0.70 | CYP3A4 (0.38) | LMNACYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL4458219 | 0.69 | CYP3A4 (0.41) | LMNACYP1A2CYP3A4PNMTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144818-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144818-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS3BP, LGALS1 | LMNA 1544/4885CYP1A2 4531/4885CYP3A4 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.